Faculty Summaries
Dr. Ross
Eric A. Ross, PhD
Associate Research Professor
  • Assistant Vice President of Biometrics and Information Sciences
  • Director, Biostatistics and Bioinformatics Facility
  • Director, Population Studies Facility
Lab Phone: 215-728-2891
Fax: 215-728-2553
Office: R383

Research Interests

  • Development of new randomized phase II clinical trial designs.
  • Application of state of the art statistical approaches to rigorously extend the quantitative interpretation of data.
  • Large-scale data integration, and the development and application of web-based technologies to enable remote data collection/presentation, health education and new interventions.
Description of research projects
Selected Publications
  1. Plimack, ER, Dunbrack, R, Brennan, T, Andrake, M, Zhou, Y, Serebriiskii, I, Wei, Q, Slifker, M, Alpaugh, K, Dulaimi, E, Palma, N, Hoffman-Censits, J, Bilusic, M, Wong, YN, Kutikov, A, Viterbo, R, Greenberg, RE, Chen, D, Lallas, CD, Trabulski, EJ, Yelensky, R, McConkey, D, Miller, VA, Golemis, E, Ross, E. Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer. Eur Urol. 2015; epub ahead of print.
  3. Weinberg DS, Myers RE, Keenan E, Ruth K, Sifri R, Ziring B, Ross E, Manne SL. Genetic and environmental risk assessment and colorectal cancer screening in an average-risk population: a randomized trial. Ann Intern Med. 2014 Oct 21;161(8):537-45. PubMed PMID: 25329201; PubMed Central PMCID: PMC4412019.
  5. Plimack ER, Hoffman-Censits JH, Viterbo R, Trabulsi EJ, Ross EA, Greenberg RE, Chen DY, Lallas CD, Wong YN, Lin J, Kutikov A, Dotan E, Brennan TA, Palma N, Dulaimi E, Mehrazin R, Boorjian SA, Kelly WK, Uzzo RG, Hudes GR. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity. J Clin Oncol. 2014 Jun 20;32(18):1895-901. PubMed PMID: 24821881; PubMed Central PMCID: PMC4050203.
  7. Min H, Ohira R, Collins MA, Bondy J, Avis NE, Tchuvatkina O, Courtney PK, Moser RP, Shaikh AR, Hesse BW, Cooper M, Reeves D, Lanese B, Helba C, Miller SM, Ross EA. Sharing behavioral data through a grid infrastructure using data standards. J Am Med Inform Assoc. 2014 Jul-Aug;21(4):642-9. PubMed PMID: 24076749; PubMed Central PMCID: PMC4078270.
  9. Handorf E, Ross EA. Uncertainty in pilot parameter estimates: A comparison of methods to size full trials. Proceedings of the American Statistical Association, Statistics Section; 2013; Toronto, Canada. c2015.
  11. Bleicher RJ, Ruth K, Sigurdson ER, Ross E, Wong YN, Patel SA, Boraas M, Topham NS, Egleston BL. Preoperative delays in the US Medicare population with breast cancer. J Clin Oncol. 2012 Dec 20;30(36):4485-92. PubMed PMID: 23169513; PubMed Central PMCID: PMC3518727.
  13. Ariazi EA, Cunliffe HE, Lewis-Wambi JS, Slifker MJ, Willis AL, Ramos P, Tapia C, Kim HR, Yerrum S, Sharma CG, Nicolas E, Balagurunathan Y, Ross EA, Jordan VC. Estrogen induces apoptosis in estrogen deprivation-resistant breast cancer through stress responses as identified by global gene expression across time. Proc Natl Acad Sci U S A. 2011 Nov 22;108(47):18879-86. PubMed PMID: 22011582; PubMed Central PMCID: PMC3223472.
  15. Schilder RJ, Pathak HB, Lokshin AE, Holloway RW, Alvarez RD, Aghajanian C, Min H, Devarajan K, Ross E, Drescher CW, Godwin AK. Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash. Gynecol Oncol. 2009 Apr;113(1):21-7. PubMed PMID: 19162309; PubMed Central PMCID: PMC2741166.
  17. Lewis JS, Meeke K, Osipo C, Ross EA, Kidawi N, Li T, Bell E, Chandel NS, Jordan VC. Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation. J Natl Cancer Inst. 2005 Dec 7;97(23):1746-59. PubMed PMID: 16333030.
  19. Stoyanova R, Clapper ML, Bellacosa A, Henske EP, Testa JR, Ross EA, Yeung AT, Nicolas E, Tsichlis N, Li YS, Linehan WM, Howard S, Campbell KS, Godwin AK, Boman BM, Crowell JA, Kopelovich L, Knudson AG. Altered gene expression in phenotypically normal renal cells from carriers of tumor suppressor gene mutations. Cancer Biol Ther. 2004 Dec;3(12):1313-21. PubMed PMID: 15662135.
  21. Evans AA, Chen G, Ross EA, Shen FM, Lin WY, London WT. Eight-year follow-up of the 90,000-person Haimen City cohort: I. Hepatocellular carcinoma mortality, risk factors, and gender differences. Cancer Epidemiol Biomarkers Prev. 2002 Apr;11(4):369-76. PubMed PMID: 11927497.
  23. Daly MB, Ross EA. Predicting breast cancer: the search for a model. J Natl Cancer Inst. 2000 Aug 2;92(15):1196-7. PubMed PMID: 10922397.
  25. Ross EA, Moore D. Modeling clustered, discrete, or grouped time survival data with covariates. Biometrics. 1999 Sep;55(3):813-9. PubMed PMID: 11315011.
  27. Hudes G, Einhorn L, Ross E, Balsham A, Loehrer P, Ramsey H, Sprandio J, Entmacher M, Dugan W, Ansari R, Monaco F, Hanna M, Roth B. Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial. J Clin Oncol. 1999 Oct;17(10):3160-6. PubMed PMID: 10506613.
  28. Bondy ML, Lustbader ED, Halabi S, Ross E, Vogel VG. Validation of a breast cancer risk assessment model in women with a positive family history. J Natl Cancer Inst. 1994 Apr 20;86(8):620-5. PubMed PMID: 8003106.
All publications